Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Axillary lymph node count is lower after neoadjuvant chemotherapy.

Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, Kim HJ, Meyers MO, Dees EC, Collichio FA, Sartor CI, Moore DT, Sawyer LR, Frank J, Klauber-DeMore N.

Am J Surg. 2006 Jun;191(6):827-9.

PMID:
16720159
2.

Number of lymph nodes identified at axillary dissection: effect of neoadjuvant chemotherapy and other factors.

Boughey JC, Donohue JH, Jakub JW, Lohse CM, Degnim AC.

Cancer. 2010 Jul 15;116(14):3322-9. doi: 10.1002/cncr.25207.

3.

Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count.

Bélanger J, Soucy G, Sidéris L, Leblanc G, Drolet P, Mitchell A, Leclerc YE, Beaudet J, Dufresne MP, Dubé P.

J Am Coll Surg. 2008 Apr;206(4):704-8. doi: 10.1016/j.jamcollsurg.2007.10.016.

PMID:
18387477
4.

Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.

Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A.

J Surg Oncol. 2006 Feb 1;93(2):109-19.

PMID:
16425290
5.

Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.

Newman EA, Sabel MS, Nees AV, Schott A, Diehl KM, Cimmino VM, Chang AE, Kleer C, Hayes DF, Newman LA.

Ann Surg Oncol. 2007 Oct;14(10):2946-52. Epub 2007 May 19.

PMID:
17514407
6.

Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.

Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE.

Am J Surg. 1998 Dec;176(6):502-9.

PMID:
9926779
7.

Will we need lymph node dissection at all in the future?

Bourez RL, Rutgers EJ, Van De Velde CJ.

Clin Breast Cancer. 2002 Dec;3(5):315-22; discussion 323-5. Review.

PMID:
12533260
8.

Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy.

Baslaim MM, Al Malik OA, Al-Sobhi SS, Ibrahim E, Ezzat A, Ajarim D, Tulbah A, Chaudhary MA, Sorbris RA.

Am J Surg. 2002 Oct;184(4):299-301.

PMID:
12383887
9.

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.

Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

Breast Cancer Res Treat. 2009 Jul;116(1):153-60. doi: 10.1007/s10549-008-0160-9. Epub 2008 Sep 12.

PMID:
18787948
10.

Lower nodal counts in axillary dissection following neoadjuvant chemotherapy: are there implications?

Callcut RA, Breslin TM.

Am J Surg. 2006 Jun;191(6):830-1. No abstract available.

PMID:
16720160
11.

Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.

Cox CE, Cox JM, White LB, Stowell NG, Clark JD, Allred N, Meyers M, Dupont E, Furman B, Minton S.

Ann Surg Oncol. 2006 Apr;13(4):483-90. Epub 2006 Mar 7.

PMID:
16523361
12.

Breast sentinel lymph node dissection before preoperative chemotherapy.

Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, Digiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR.

Arch Surg. 2008 Jul;143(7):692-9; discussion 699-700. doi: 10.1001/archsurg.143.7.692.

PMID:
18645113
13.

Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.

Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN.

Ann Surg Oncol. 2002 Apr;9(3):235-42.

PMID:
11923129
14.

Factors affecting axillary lymph node retrieval and assessment in breast cancer patients.

Cil T, Hauspy J, Kahn H, Gardner S, Melnick W, Flynn C, Holloway CM.

Ann Surg Oncol. 2008 Dec;15(12):3361-8. doi: 10.1245/s10434-008-9938-6. Epub 2008 Oct 1.

PMID:
18830666
15.

Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?

Cheung TT, Suen DT, Kwong A.

ANZ J Surg. 2009 Oct;79(10):719-23. doi: 10.1111/j.1445-2197.2009.05057.x.

PMID:
19878167
16.

Implementation of sentinel node biopsy in breast cancer patients in the Netherlands.

Ho VK, van der Heiden-van der Loo M, Rutgers EJ, van Diest PJ, Hobbelink MG, Tjan-Heijnen VC, Dirx MJ, Reedijk AM, van Dijck JA, van de Poll-Franse LV, Schaapveld M, Peeters PH.

Eur J Cancer. 2008 Mar;44(5):683-91. doi: 10.1016/j.ejca.2008.01.027. Epub 2008 Mar 7.

PMID:
18314328
17.

Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.

Navarro-Cecilia J, Dueñas-Rodríguez B, Luque-López C, Ramírez-Expósito MJ, Martínez-Ferrol J, Ruíz-Mateas A, Ureña C, Carrera-González MP, Mayas MD, Martínez-Martos JM.

Eur J Surg Oncol. 2013 Aug;39(8):873-9. doi: 10.1016/j.ejso.2013.05.002. Epub 2013 May 25.

PMID:
23711734
18.

Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node.

Rivers AK, Griffith KA, Hunt KK, Degnim AC, Sabel MS, Diehl KM, Cimmino VM, Chang AE, Lucas PC, Newman LA.

Ann Surg Oncol. 2006 Jan;13(1):36-44. Epub 2006 Jan 1.

19.

Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.

Khan A, Sabel MS, Nees A, Diehl KM, Cimmino VM, Kleer CG, Schott AF, Hayes DF, Chang AE, Newman LA.

Ann Surg Oncol. 2005 Sep;12(9):697-704. Epub 2005 Aug 4.

20.

Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer.

Noguchi M.

Eur J Surg Oncol. 2008 Feb;34(2):129-34. Epub 2007 May 11. Review.

PMID:
17498911

Supplemental Content

Support Center